Who invested in InCarda Therapeutics

3 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$5.5Mraised across 3 rounds since 2012, from 3 sources

$310KDebt$156KVenture$5.0MSeries A

Latest round: Series A, $5.0MApr 2015
Step-upi: 32.1×
Investors: 1

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201320142015

$310KDebt$156KVenture$5.0MSeries A

First round: Debt, $310K
Biggest round: $5.0M
Usual gap between rounds: 20 months

The rounds

Apr 2015
Series A$5.0M1 new
- Morningside Private Investors
From a historical funding record
Sept 2013
Venture$156K
No investor was named in the report.
Reported by sec.govSEC filing: $156K sold, first sale Sept 2013
Oct 2012
Debt$310K
No investor was named in the report.
Reported by sec.govSEC filing: $310K sold, first sale Jul 2011

Founders and team

From InCarda Therapeutics's own website and the SEC filings it signed: 5 on the team.

Dr. Luiz BelardinelliCEO
Dr. Myles GreenbergCEO
Julie RogersClinical Manager
Leo SantanaController
Grace ColonExecutive Officer, Directori

On the board, as filediAlan ColowickAndrew ElBardissiDan WelchIsaac ChengJohan Christenson

Everyone who backed them

Morningside Private InvestorsGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list InCarda Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.